Skip to content

This Site is Intended for Healthcare Professionals Only

Search AI Powered

Latest Stories

CMA slaps Advanz with £100 million in fines for over pricing of thyroid drug

The Competition and Markets Authority (CMA) has imposed more than £100 million in fines on Advanz for inflating the price of thyroid tablets.

The pharma firm, Advanz increased the price of thyroid tablet packs from £20 in 2009 to £248 in 2017 – an increase of 1,110 per cent. 


Following an investigation, the CMA found that from 2009 until 2017 Advanz charged excessive and unfair prices for supplying liothyronine tablets which are used to treat thyroid hormone deficiency.

The CMA has fined the firms involved a total of over £100 million for the relevant periods in which they broke the law: Advanz (£40.9 million), together with HgCapital (£8.6 million) and Cinven (£51.9 million) – two private equity firms which were previously owners of the businesses now forming part of Advanz.

The price increases were not driven by any meaningful innovation or investment, volumes remained broadly stable, and the cost of producing the tablets did not increase significantly. NHS spending on the tablets in 2006, the year before the implementation of the strategy, was £600,000, but by 2009 had increased to more than £2.3 million and jumped to more than £30 million by 2016.

Eventually the drug was placed on the NHS ‘drop list’ in July 2015. This led to patients being faced with the prospect of having their current treatment stopped or having to purchase liothyronine tablets at their own expense. That is particularly concerning, given that many patients do not respond adequately to the main treatment for hypothyroidism, levothyroxine tablets – and instead rely on liothyronine tablets to alleviate symptoms such as extreme fatigue and depression.

Andrea Coscelli, Chief Executive of the CMA, said: “Advanz’s decision to ratchet up the price of liothyronine tablets and impose excessive and unfair prices for over eight years came at a huge cost to the NHS, and ultimately to UK taxpayers. But that wasn’t all – it also meant that people dealing with depression and extreme fatigue, as a result of their thyroid conditions, were told they could not continue to receive the most effective treatment for them due to its increased price.

“Advanz’s strategy exploited a loophole enabling it to reap much higher profits. This fine of over £100 million, and our work in the pharma sector to date, send a clear message that breaking the law has serious consequences.”

As well as imposing substantial fines, the CMA’s decision makes it easier for the NHS to seek compensation for the firms’ behaviour, by way of damages, should it choose to do so.

More For You

Pharmacy students Learning Support Fund

Pharmacy students will be included in the Travel and Dual Accommodation Expenses section of the NHS Learning Support Fund.

iStock

Pharmacy students to have access to Learning Support Fund

FOR the first time in England, pharmacy students will be eligible to reimburse travel and accommodation costs while attending placements.

The Department of Health and Social Care confirmed that pharmacy students would finally be included in the Travel and Dual Accommodation Expenses (TDAE) section of the NHS Learning Support Fund (LSF).

Keep ReadingShow less
NHS for robotic surgery

Patients undergoing robotic surgery are able to recover quicker and be discharged sooner.

Pic credit: iStock

NHS pushes for robotic surgery to reduce waiting time, improve outcomes

The NHS is planning to step up robotic surgery over the next decade to reduce waiting time, help in the speed of recovery of patients, and shorter hospital stay.

As per the NHS projections, the number is expected to zoom from 70,000 in 2023/24 to half a million by 2035.

Keep ReadingShow less
Scotland's digital patient care record

The amendment ensures that every person who receives health care or a social service in Scotland will have a digital care record

Pic credit: iStock

Scotland's move to create digital patient care record hailed

The Royal Pharmaceutical Society (RPS) in Scotland has welcomed the decision of the Scottish Parliament to create an integrated digital patient care record.

The move came during a debate on the Care Reform (Scotland) Bill on Tuesday (10), when Jackie Baillie tabled an amendment to ensure that every person who receives health care or a social service in Scotland has a digital care record.

Keep ReadingShow less
A woman using a period tracker app

Cambridge University academics have flagged concerns over the safety of period tracker apps

Pic credit: iStock

Users of period tracking apps face privacy, safety risk, say experts

The report said the apps provide a "gold mine" of data for consumer profiling and warn that in the wrong hands it could pose a safety risk

CAMBRIDGE UNIVERSITY academics have flagged concerns over the safety of period tracker apps and warned that the women using them could face privacy and safety risks.

Keep ReadingShow less
Patients to get test results via NHS app

An investment of £50m has been made to upgrade the NHS app

Patients to get test results via NHS app

Millions of patients will now be able to access test results and get appointment reminders on their smartphones as the government tries to position the NHS app as the default mode of communication and steer away from traditional methods like letters.

An investment of £50m has been made to upgrade the NHS app and the health service hopes to save £200m over the next three years.

Keep ReadingShow less